FOR IMMEDIATE RELEASE ON June 20, 2012
Clinical Trial: Deep Brain Stimulation Helps Parkinson鈥檚 Patients Over Long Term
MINNEAPOLIS -
Deep brain stimulation appears to help people with Parkinson鈥檚 disease over the long term, according to the first randomized clinical trial to look at its effect on patients鈥 motor symptoms three years later. The study is published in the June 20, 2012, online issue of the medical journal of the . For the study, 159 people with Parkinson鈥檚 disease randomly assigned to deep brain stimulation of the globus pallidus interna (GPi) or subthalamic nucleus (STN) of the brain were followed for three years. Participants reported motor symptoms in a diary for 30 minutes every half hour for two days before each of the six study visits. Medication use was allowed in the study. 鈥淧ast studies have had mixed results about which area of the brain benefits the most from deep brain stimulation,鈥 said study author Frances M. Weaver, PhD, with Hines Veterans Administration Hospital and Loyola University Stritch School of Medicine in Maywood, Ill. 鈥淚n our study, deep brain stimulation of both areas improved motor symptoms by 32 percent on average over the course of three years. However, deep brain stimulation of the GPi region of the brain was associated with a slower decline in thinking skills. More research will help us to find out whether medication or the deep brain stimulation was responsible for these differences.鈥 The study does have one major limitation, according to accompanying editorial author Michele Tagliati, MD, with Cedars-Sinai Medical Center in Los Angeles and a Fellow of the 好色先生. 鈥淎 fairly large amount, or about 50 percent, of the initial participants could not be observed at three years due to the original study design and timeline. However, these data provide more reliable evidence that the improvement of motor symptoms of Parkinson鈥檚 disease by deep brain stimulation remains stable over the long term regardless of the area in the brain in which the deep brain stimulation occurs,鈥 said Tagliati. The study was supported by the Cooperative Studies Program, the Department of Veterans Affairs Office of Research and Development, and the National Institute of Neurological Disorders and Stroke, with additional funding from Medtronic Neurological, Inc. To learn more about Parkinson鈥檚 disease, visit .